FY2027 Earnings Estimate for BMY Issued By William Blair

Key Points

• William Blair has revised its FY2027 earnings per share estimate for Bristol Myers Squibb from $6.29 to $6.36, although this remains below the consensus estimate of $6.74.
• The latest quarterly earnings report showed Bristol Myers Squibb topping analysts' expectations with $1.46 EPS for the quarter, compared to a consensus estimate of $1.07.
• The company recently paid a quarterly dividend of $0.62, resulting in an annualized dividend yield of 5.2% and a payout ratio of 100%.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Analysts at William Blair raised their FY2027 earnings estimates for Bristol Myers Squibb in a report released on Tuesday, September 2nd. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will earn $6.36 per share for the year, up from their prior forecast of $6.29. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share.

BMY has been the topic of several other research reports. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. Wall Street Zen lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Citigroup dropped their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research report on Friday, August 1st. Finally, Daiwa America lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Bristol Myers Squibb presently has a consensus rating of "Hold" and a consensus price target of $56.38.

Bristol Myers Squibb Stock Performance

BMY stock traded up $0.39 during midday trading on Wednesday, hitting $47.08. 8,227,003 shares of the stock traded hands, compared to its average volume of 9,276,282. The firm has a market cap of $95.84 billion, a P/E ratio of 18.99, a PEG ratio of 2.41 and a beta of 0.35. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The stock's fifty day simple moving average is $47.09 and its 200-day simple moving average is $50.48. Bristol Myers Squibb has a 1-year low of $42.96 and a 1-year high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. The firm had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business's quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.

Hedge Funds Weigh In On Bristol Myers Squibb

Hedge funds and other institutional investors have recently modified their holdings of the business. New England Asset Management Inc. lifted its stake in shares of Bristol Myers Squibb by 0.8% in the first quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company's stock worth $2,408,000 after buying an additional 305 shares in the last quarter. Commonwealth Equity Services LLC increased its position in shares of Bristol Myers Squibb by 1.1% during the first quarter. Commonwealth Equity Services LLC now owns 1,288,407 shares of the biopharmaceutical company's stock valued at $78,580,000 after acquiring an additional 13,959 shares during the last quarter. Polar Asset Management Partners Inc. acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at about $16,651,000. Avaii Wealth Management LLC increased its stake in Bristol Myers Squibb by 590.9% during the 1st quarter. Avaii Wealth Management LLC now owns 78,597 shares of the biopharmaceutical company's stock worth $4,794,000 after buying an additional 67,221 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in Bristol Myers Squibb by 1.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 65,038 shares of the biopharmaceutical company's stock worth $3,967,000 after acquiring an additional 869 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares of the company's stock, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.09% of the company's stock.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were paid a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.3%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.